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How to use inotropes is one of the most controversial topics in the management
of heart failure. While most clinicians use these drugs, and recognize the state of
inotrope dependency, current guidelines recommend them onlu as a bridge or
palliation. Thus, inotropes are considered either neutral or detrimental in terms of
outcomes. Meanwhile, properly designed randomized clinical trials testing the
outcomes on inotropes, have never been performed and it is unlikely that they
will ever be attempted. These trials would require randomizing patients with
advanced heart failure, low output syndrome, and impaired end-organ perfusion
into groups that received or not received inotropes, or received inotropes or
placebo. Many physicians would consider this design unethical so the trials
would be challenging to implement. But if it is unethical to deny inotropes to this
subset of patients, we have to admit that inotropes do not only improve quality of
life, but prolong it, or decrease mortality. Otherwise, we consider it unethical to
deny the medication which increases mortality.

Accepted: June 26, 2015
Published: June 26, 2015
© 2015 The Author(s). This is an
open access article published
under the terms of the Creative
Commons
AttributionNonCommercial 4.0 International
License
(https://creativecommons.org/lice
nses/by-nc/4.0/), which permits
unrestricted non-commercial use,
distribution, and reproduction in
any medium, provided that the
original
author(s)
and
the
publication source are credited.

interests:

Keywords
Inotropes; heart failure

Funding: Not applicable
Competing
applicable

In this review, we analyze the current evidence relating to inotropes and
outcomes. We demonstrate that the original trials were performed with agents
that are no longer in use, or on patients without an indication for inotropes, or at a
time before automatic cardio-defibrillators were recommended for primary
prevention. We conclude that current guidelines for inotropes are misleading in
their interpretation of outcomes in patients with advanced heart failure. The
guidelines should be revised to adequately reflect the evidence.
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Introduction
The role of inotropes in management of heart failure (HF) is changing.
Mechanical circulatory support (MCS) offers increased survival and improved
quality of life, far beyond the potential of inotropes. Nevertheless, many
cardiologists still use them. It is much easier for the patient to accept continuous
intravenous infusion of another drug, than to agree to an open heart surgery with
implantation of hardware which requires serious maintenance and chronic
anticoagulation. With rare exceptions, the left ventricular assist device (LVAD)
implant is irreversible. Unlike medicine, it changes the lifestyle for a long time, till
heart transplant, or forever. To the contrary, being on an inotrope is much less
demanding. Because so many patients still remain on inotropes for months or
even years, we want to clarify the issue of increased mortality, linked to the
inotrope use.
At present, the use of inotropic agents in the management of HF is
controversial. On one hand, specialists who manage patients with advanced HF
utilize them widely. The Acute Heart Failure Global Survey of Standard
Treatment (ALARM-HF) global survey of 666 hospitals in nine countries showed
that inotropes were used in 39% of all admissions for acute HF 1. In the
Randomized Evaluation of Mechanical Assistance for the Treatment of
Congestive Heart Failure (REMATCH) trial, 72% of patients in the medical arm
and 65% of patients in the ventricular assist device arm were on inotropes 2.
Indeed, the HF community uniformly recognizes the state of “inotrope
dependency”. On the other hand, current guidelines caution that these drugs may
be potentially detrimental: “Despite improving hemodynamic compromise,
positive inotropic agents have not demonstrated improved outcomes in patients
with HF in either the hospital or outpatient setting” 3.
Current Guidelines on Inotropes
Guidelines of the American College of Cardiology Foundation/American Heart
Association (ACCF/AHA) (2013)3, Heart Failure Society of America (2010) 4,
European Society of Cardiology (2012) 5, and International Society for Heart and
Lung Transplantation 6-8 have recommendations on inotropes in HF. The
recommendations of various societies are summarized in Table 1. In general,
inotropes are indicated in the presence of acute or chronic hemodynamic
compromise with end organ dysfunction due to low output, and are considered to
be detrimental and contraindicated if this syndrome is not present.
Specifically, the ACCF/AHA guidelines state that use of parenteral inotropic
agents in hospitalized patients without documented severe systolic dysfunction,
low blood pressure, or impaired perfusion, and evidence of significantly
depressed cardiac output, with or without congestion, is potentially harmful 3.
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These recommendations are based on profound understanding on
pathophysiology of HF. As the disease progresses over time, the heart maintains
normal cardiac output, but at the cost of rising left ventricular end diastolic
pressure (Figure 1). The mainstay intervention at these stages is diuretic therapy,
which decreases intracardiac filling pressures (congestion), along with
medications favoring left ventricular reverse remodeling such as angiotensin
converting enzyme inhibitors. Eventually, compensatory mechanisms fail, and
cardiac output decreases. Only at this advanced stage, inotropes can be
beneficial. Because low output is not present at the earlier stages, administration
of inotropes cannot be favorable but can certainly cause harm because of side
effects.
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NYHA II-III
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NYHA IV

LV Pressure
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Figure 1. Hemodynamics in Heart Failure: a Progression (from Barry Borlaug,
with permission)

Inotropes: Hemodynamic Effects
Milrinone and dobutamine are currently the only two inotropes approved for use
in the United states and both exert their actions by increasing the intracellular
level of cyclic adenosine monophosphate 9. Dobutamine achieves this effect
indirectly through adrenergic agonism while milrinone, a phosphodiesterase
inhibitor, directly blocks cyclic monophosphate breakdown 10. We reviewed the
mechanism of action of both drugs in previously published paper 11.
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Table 1. Guideline recommended indications for inotropic agents in heart failure

Guidelines

American College of
Cardiology
Foundation/American
Heart Association
20133

European Society of
Cardiology 2012 5

Heart Failure Society
of America 2010 4

International Society
for Heart and Lung
Transplantation 2006 6

Strength

Level of
Evidenc
e

Cardiogenic shock, until definitive therapy (e.g., coronary revascularization, MCS,
heart transplantation) or resolution of the acute precipitating problem

I

C

“Bridge therapy” in stage D refractory to guideline determined medical therapy and
device therapy, while awaiting MCS or cardiac transplantation

IIA

B

Severe systolic dysfunction with low blood pressure and significantly depressed
cardiac output in hospitalized patients

IIB

B

Palliative therapy for symptom control in select patients with stage D despite optimal
guideline determined therapy, not eligible for either MCS or cardiac transplantation

IIB

B

Long-term IV inotropes, in the absence of specific indications or for reasons other
than palliative care, are potentially harmful

III

B

Inotropes in hospitalized patients without severe systolic dysfunction, low blood
pressure, or impaired perfusion, and evidence of significantly depressed cardiac
output, with or without congestion, is potentially harmful .

III

B

Inotropes should be considered in patients with hypotension (systolic blood pressure
<85 mmHg) and/or hypoperfusion

IIA

C

Inotropes are NOT recommended unless there is hypotension (systolic blood
pressure <85 mmHg), hypoperfusion, or shock because of safety concerns (atrial
and ventricular arrhythmias, myocardial ischaemia, and death).

III

C

IV inotropes may be considered to relieve symptoms and improve end-organ
function in HF with LV dilation, reduced LVEF, and diminished peripheral perfusion
or end-organ dysfunction (low output syndrome), particularly if systolic blood
pressure is <90 mm Hg, in symptomatic hypotension despite adequate filling
pressure, or unresponsiveness/intolerance of IV vasodilators.

may be
considered

C

Inotropes may be considered in similar patients with evidence of fluid overload if
they respond poorly to IV diuretics or have diminished/ worsening renal function.

may be
considered

C

IV inotropes are not recommended unless left heart filling pressures are elevated or
cardiac index is severely impaired

not recommended

C

In patients with decompensated HF and hypoperfusion in spite of adequate filling
pressures, inotropic or pressor therapy should be used.

I

C

Long-term use of inotropic therapy should only be used as a pharmacologic bridge
to transplantation or for palliation.

I

C
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The magnitude of hemodynamic effects of the inotropes on cardiac index and
cardiac output is remarkable. Insurance carriers look for a 20% increase in
cardiac index or a similar decrease in pulmonary wedge pressure, in order to
issue an approval for continuous home inotropes 12. However, greater response
is common, with a twofold increase in cardiac index commonly observed 13.
Milrinone in currently approved doses typically increases cardiac index by 2442%, decreases pulmonary capillary wedge pressure by 24- 33%, and reduces
systemic vascular resistance by 15- 31%, with dose-dependent effect. The drug
is effective in most patients, and those with the worst hemodynamic profile at
baseline derived the most benefits 12.
Most of hemodynamic effects of dobutamine and milrinone are similar
dobutamine and milrinone




14.

Both

Increase cardiac output
Cause peripheral vasodilation
Decrease pulmonary capillary wedge pressure

There are some differences between dobutamine and milrinone 15-18
Dobutamine, in comparison with milrinone, causes
 Greater increase in heart rate
 Greater increase in myocardial oxygen consumption
 Greater proarrhythmic effect, including ventricular tachycardia
 Effects are attenuated in patients who receive beta blockers

19,20

Milrinone, in comparison with dobutamine, causes
 More hypotension
 Greater reduction in left and right heart filling pressures
 Greater reduction in mean arterial pressure
 Greater reduction in pulmonary arterial pressure
 Longer duration of action after discontinuation of the drip,
especially in the presence of renal dysfunction
 Greater hemodynamic effects in general when the patient is on
beta blockers
In direct comparison of dobutamine and milrinone, Colucci et al.17 found that
milrinone caused a significantly greater reduction in left and right heart filling
pressures and mean arterial pressure than did dobutamine, and for any given
increase in dP/dt, milrinone caused a greater reduction in systemic vascular
resistance than did dobutamine. Hemodynamic effects of dobutamine were
blunted in patients with severe HF and elevated serum norepinephrine, most
likely due to desensitization of myocardial beta 1 adrenoreceptors.
The biggest difference between the two especially in our expanding health care
system may be cost. Dobutamine is cheaper 21,22. For a course of in-hospital
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inotrope therapy, total acquisition cost of milrinone was significantly higher than
that of dobutamine (16,270 dollars +/- 1334 versus 380 dollars +/- 533 P
<.00001)21. In terms of arrhythmogenicity, dobutamine causes atrial and
ventricular arrhythmias more commonly than milrinone, although both agents
have proarrhythmic potential and hence both require continuous rhythm
monitoring, at least while in the hospital. Milrinone causes nonsustained
ventricular tachycardia in 3.7% of patients and sustained ventricular tachycardia
in 0.5% 12.
Overall, hemodynamic properties of inotropes seem to be optimal for low output,
or “cold” HF patients, especially if they are also “wet”23, i.e. have volume overload
and increased intracardiac pressures. It is well known that this type of HF
patients has the worst prognosis 24. Besides, increase in cardiac output and
decrease in congestion frequently results in improved urine output, a
phenomenon widely known to HF doctors 16,25.
It is quite counterintuitive that drugs with such remarkable hemodynamic effects
can be detrimental in advanced HF.
Table 2. Properties of dobutamine and milrinone
Inotrope

Dose

Onset and
Duration of
action

Side effects

Dobutamine

2.5 to 20
μg/kg/min IV

Onset of action
is 1 to 10 min,
peak effect 10
to 20 min. The
half-life is 2
min

Ventricular ectopy,
tachycardia,
hypotension, angina,
palpitations, fever,
headache, nausea

Milrinone

0.25 to 0.75
μg/kg/min IV

Onset of action
is 5 to 15 min.
The half-life is
2.5 hours

Ventricular and
supraventricular
arrhythmias, angina,
hypotension, headache

Inotrope Dependency
The term “inotrope-dependent” is used liberally in the guidelines, without a formal
definition. Patients are characterized as inotrope dependent if they cannot be
weaned off inotropes at an experienced HF center 4. Inotrope dependence
means that withdrawal of inotropes leads to symptomatic hypotension, recurrent
congestive symptoms, or worsening renal function 26. It is recognized that
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symptoms and not purely the values of re-measured hemodynamic parameters
have to be considered when deciding on inotrope dependence 26.
The inotrope dependency is particularly important when determination of the
need for advanced HF therapies such as heart transplantation or ventricular
assist device. Profile one, or “crush and burn”, includes patients who rapidly
decline despite inotropes, profile two patients decline more gradually but still
“Sliding on inotropes.” Profile three includes most stable patients who still need
to be on inotropes, with the description “stable blood pressure, organ function,
nutrition, and symptoms on continuous intravenous inotropic support (or a
temporary circulatory support device or both), but demonstrating repeated failure
to wean from support due to recurrent symptomatic hypotension or renal
dysfunction: “dependent stability.”27
The HFSA guidelines state that “these agents may help relieve symptoms due to
poor perfusion and preserve end-organ function in patients with severe systolic
dysfunction and dilated cardiomyopathy”4 End organ function in HF is usually
related to hepatic and renal function. If inotropes help preserve liver and kidney
function, they ought to prolong life, or to “avoid imminent death”28. The best
definition of inotrope dependency we found in the paper by Hershberger et al.28:
“Inotropic dependence was defined as the failure to wean from inotropes
because of imminent (minutes to hours) worsening of the patient’s clinical status
(combined objective [eg, blood pressure, level of consciousness, confusion,
change in creatinine, oxygenation] and subjective [eg, dyspnea, confusion,
weakness]), such that death appeared imminent, and the patient was deemed
highly unlikely to survive inotrope withdrawal to permit hospital discharge”. The
authors state further that the attempted withdrawal of inotropic support in this
cohort of patients can be acutely life-threatening 28.
If we recognize that patients on inotropes cannot be weaned off of them, we have
to admit that inotropes reduce mortality in this terminal end stage HF population.
Otherwise, the term “inotrope dependent” becomes oxymoranical.
Inotrope dependency is the condition, which makes it unfeasible and ethically
unacceptable to conduct any randomized controlled trials on inotropes versus
placebo or inotrope versus no inotrope. The only comparison possible is one
inotrope versus another, or inotropes versus a different mean of inotropic
support, like in the REMATCH (Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive Heart Failure) trial 2. Indeed, Lynne
Stevenson wrote in 2003 16 that randomized trials performed with and without
inotropic infusions during HF hospitalizations have selected patients in whom
intravenous therapy was not considered essential for management. Hershberger
et al. also wrote that a randomized clinical trial designed to remove dobutamine
from patients deemed inotrope-dependent would cause considerable discomfort
from an ethical perspective 28. Ten years later, this statement still holds true. But
if you enroll only patients in whom the intervention is not essential, you cannot
establish the value of the very intervention that is tested.
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Patterns of Inotrope Use
There are three distinct patterns of intravenous inotrope use: confined to hospital
admission, intermittent home infusions (usually several times per week at the
infusion center), and the infusions started in the hospital and continued at home
continuously, weeks to months and even years in duration. In the past, some
inotropes were also used orally in the outpatient setting. Below, we briefly
summarize non-randomized studies based on the setting of infusion. The studies
where patients were randomized into inotrope versus placebo or inotrope versus
no inotrope, regardless of the setting where infusion was performed, are
summarized in Tables 3-5 in the end of the manuscript. All studies, in the text
and in the table, include patients with symptomatic HF and decreased left
ventricular ejection fraction.
Hospital Infusions


Some studies report the experience with in-hospital inotrope
infusions when the patients were admitted not because of
hemodynamic compromise and low output syndrome, but
electively. A three-day dobutamine infusion in 29 patients resulted
in hemodynamic and metabolic improvement, including elevation
of sodium and improvement in renal function 29



Intravenous milrinone given to 14 patients resulted in improved
hemodynamics and allowed higher doses of diuretics and other
HF medications. Oral angiotensin-converting enzyme inhibitor and
diuretic doses were increased by 318% and 89%, respectively.
NYHA functional class improved from 3.8 +/- 0.4 to 2.6 +/- 0.6
following therapy, and there was a reduction in hospital
admissions in 10 patients who responded to therapy during the
subsequent year compared with the year before treatment (4 +/17 versus 17 +/- 15) 30.



Intermittent
infusions
of
either
dobutamine
(43
patients) or nitroprusside was given to a total of 113 patients for
about a month. There was a higher re-hospitalization rate (86%
versus 57%, p<0.02) and higher mortality (58% versus 28%) in the
dobutamine group. The decision of using dobutamine versus
nitroprusside was made by individual physicians. Baseline systolic
blood pressure was 90 mmHg in the dobutamine group and 95
mmHg in the nitroprusside group; there is no indication whether
this difference was significant. Heart transplantation was done in
78 % of those on dobutamine and only in 48% of those on
nitroprusside 31.
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In 261 patients, in-hospital infusion of nesiritide in two different
doses was compared with dobutamine. Six-month mortality was
lower in the nesiritide groups 32.

This last study was designed to compare the outcomes in patients with infusion
of nesiritide in a lower and higher dose versus any other vasoactive drug, at the
discretion of the investigator, and patients were randomized into these three
arms. Some patients in the arm with vasoactive drug were on dobutamine. The
comparison between nesiritide and dobutamine was therefore a comparison
between non-randomized groups, with very limited number of baseline
characteristics and no invasive hemodynamic information. Moreover, mean
baseline systolic blood pressure was 120 mmHg, and blood pressure below 90
mmHg was an exclusion criterion. Consequently, the study omitted all patients
with low output HF syndrome, fundamentally excluding the only patients with an
indication for dobutamine use. This essential design flaw makes the study
inconclusive. The study of Capomolla et al. 31 is also inconclusive due to lack of
randomization.
Comparison of dobutamine versus milrinone in hospitalized patients, awaiting
heart transplantation, did not show a clear advantage of one or the other in terms
of right heart hemodynamics, death, need for additional vasodilator/inotropic
therapy, need for mechanical cardiac support before transplantation, or
ventricular arrhythmias requiring increased antiarrhythmic therapy 21.
Intermittent home infusions
Historically, intermittent infusions of inotropes were used as a treatment for end
stage HF with severe symptoms (NYHA III/IV). This practice is no longer
supported and is a Class III recommendation per ACC/AHA3. We summarized
the outcomes in our previous article 11. Randomized controlled trials are included
into Tables 3-5.
Continuous home infusions
Continuous inotrope infusion at home is more relevant to today’s practice than
intermittent treatments. Such infusion may be used to improve symptoms and to
better quality of life in hospice patients, in addition to acting as a bridge to cardiac
transplant in candidates awaiting a donor. A decrease in the need for HF
hospitalizations after initiation of continuous home inotrope infusions was
suggested by the analysis of the Medicare data 33.


Continuous home infusion of dobutamine or milrinone in 24 and 7
patients, respectively, resulted in improvement in NYHA functional
class from 4.0+/-0.0 to 2.7+/-0.9 (p<0.0001), decrease of number
of hospital admissions and length of stay from 20.9+/-12.7 to
5.5+/-5.4 days (p=0.0004), as well as a 16% reduction in cost of
care in comparison to control period preceding the therapy 34.
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Continuous home infusion of milrinone was used in 60 heart
transplant candidates and resulted in hemodynamic and
symptomatic improvement as well as cost reduction, with 88.3% of
patients eventually undergoing heart transplant 35.



Continuous home infusion of milrinone was given to 29 heart
transplant candidates and resulted in hemodynamic and
symptomatic improvement 36



Continuous home infusion of milrinone (8 patients) or dobutamine
(12 patients) given as a bridge to cardiac transplantation, resulted
in improvement of functional status, serum creatinine, better
hemodynamic parameters, and decreased number of
hospitalizations during positive inotropic infusion therapy when
compared with pre-treatment baseline 37



Continuous home infusion of dobutamine (4 patients), dopamine
(13 patients), or the combination of both (6 patients) resulted in
reduction of the number of days spent in the hospital 38



Continuous (4 patients) and intermittent (7 patients) home infusion
of dobutamine in 11 patients resulted in symptomatic improvement
39

The number of reported deaths while on inotropes varied greatly among the
studies, but since there were no control groups, and same patients’ historical
data were used as control, no conclusion about mortality can be derived.

Mortality Data and Randomized Studies
There is a relative paucity of randomized control studies on the mortality
effect of inotropes in HF. Thus, to date, much of the data on the subject has
been drawn from retrospective analysis. Overall, the data suggests that mortality
of patients treated with intravenous inotropes is high. In the Evaluation Study of
Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness
(ESCAPE) trial, six month mortality in patients with HF receiving inotropes during
hospitalization reached 19% 40, while the analysis of the Medicare data indicated
that in patients treated with continuous home inotrope infusion, a six month
mortality exceeded 40% 33. Analysis of the Acute Decompensated Heart Failure
National Registry (ADHERE), showed that inotropic treatment with dobutamine
and milrinone was associated with a 200% increase of in-hospital mortality in
comparison to vasodilators 41. However, baseline characteristics of the patients
on inotropes, such as systolic blood pressure over 120 mmHg, demonstrate that
they did not have low output syndrome. Only 8% of patients, started on
inotropes, had systolic blood pressure less than 90 mmHg.
The VAD Journal: http://dx.doi.org/10.13023/VAD.2015.09
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Moreover, the Flolan International Randomized Survival Trial (FIRST),
determined that six month mortality among patients on dobutamine was 70%,
with dobutamine being the strongest independent predictor of mortality in the
study 42. Use of dobutamine or milrinone was consistent with very poor
prognosis, even in comparison with other intravenous vasoactive drugs like
vasodilators 41. The addition of more than one inotrope is associated with further
mortality increase 43. High mortality rate alone, however, does not in itself prove
that inotropes are detrimental. Indeed, mortality is expected to be high by virtue
of the advanced disease states in those who require inotropes.
Meta-analyses and retrospective analyses examining the mortality effect
of inotropes in HF have been largely mixed. A meta- analysis of multiple
placebo-controlled trials by Thakray et al. 44 failed to demonstrate increased
mortality on inotropes, while another meta-analysis on phosphodiestherase-3
inhibitors showed poorer outcomes on these agents 45. In another retrospective
study, no mortality difference was found between dobutamine and milrinone at
home in a single center experience 46, although milrinone was deemed more
effective as a bridge to transplant, allowing more patients to be bridged by
inotropes alone, without the need for mechanical circulatory support. Also, renal
and hepatic function improved on milrinone 47.
Some suggestions of increased mortality on inotropes come from post-hoc
analyses of trials not designed to test the outcomes on inotropes where no
randomization on inotrope versus no inotrope or placebo was conducted. For
example, the FIRST trial was a randomized, controlled trial, designed to test the
effects of continuous intravenous epoprostenol plus conventional therapy versus
conventional therapy alone in patients with advanced HF. Some patients who
entered the trial were also on intravenous dobutamine 42. The analysis of the
outcomes depending on the use of dobutamine is therefore flawed because the
patients who required inotropes were sicker (89% in NYHA IV) than those who
did not (53%).
We grouped the randomized trials on inotropes into three categories:
trials that demonstrate negative effects of inotropes on clinical outcomes, those
that show neutral effects, and those that show beneficial effects of inotropes
(Table 3).
Increased mortality was found on oral enoximone 48,49, oral vesnarinone
50, oral ibopamine 51, oral milrinone 51,52, and beta agonist xamoterol.
Vesnarinone was associated with a dose-dependent increase in mortality mostly
due to arrhythmic death 50. None of these inotropes is currently in use, for the
very reason of being associated with high mortality, and hence none of these
outcomes are pertinent to the effects of intravenous dobutamine or milrinone.
Besides, inotropes are proarrhythmic, and sudden cardiac death is considered
the main mechanism responsible for excess mortality on inotropes 50. Meanwhile,
all the above studies were conducted before the time when implantation of
automatic cardioverters-defibrillators had become the routine. Today, many of
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the patients on inotropes are implanted with defibrillators by the time they are
inotrope dependent, and they are largely protected from arrhythmic death.
Indirectly, this consideration is confirmed by the study of Drakos et al.
Due to concern that arrhythmia might contribute to inotrope-induced mortality,
they compared end stage HF patients on intermittent inotropes versus
conventional medical management, adding oral amiodarone to both groups
(inotropes were represented by either dobutamine or levosimendan). The study
was not randomized. The 6-month (51% versus 18%) and 1-year (36% versus
9%) survival rates were significantly higher (p = 0.001 for both), and functional
status was better, in patients on inotropes and amiodarone 53. Earlier, the same
group of authors demonstrated similar results in a randomized placebo controlled
study (see Tables 3-5) 54.
The majority of randomized studies are neutral demonstrating neither
benefit nor detriment of inotropes. In the Outcomes of a Prospective Trial of
Intravenous Milrinone for Exacerbations (OPTIME-CHF) trial of 951 patients
admitted for acute decompensated HF, there were no significant differences of in
hospital mortality, 60 day mortality or combined 60 day death when comparing
milrinone versus placebo 55. Post hoc subgroup analysis did reveal an increase
in a composite of death or re-hospitalization in patients with coronary artery
disease treated with milrinone versus placebo (42% versus 36%), although no
difference was found between the two groups in non-ischemic patients 56. The
ESSENTIAL trial examined the effect of low dose enoximone on patients with
advanced HF on optimal medical therapy, and also showed no mortality
difference 57. In another study, oral enoximone used for weaning from
intravenous inotropes, did not affect the mortality 58. Other authors 59-65 also
reported no difference in terms of mortality between inotropes and placebo.
Conversely, relatively few studies demonstrated beneficial effects of
inotropes on mortality. Similarly to those trials showing increased mortality, most
studied agents are not currently in use and therefore not very pertinent:
enoximone 58,66, vesnarinone 67, amrinone 68. The only study on dobutamine in
this group used it in combination with amiodarone to negate potential
proarrhythmic effects. Mortality reduction on dobutamine plus amiodarone versus
placebo plus amiodarone had hazard ratio of 0.403 (95% confidence intervals
0.164 -0.992; p = 0.048).
But the main observation from reading reports of inotrope use,
randomized or not randomized, is that very few authors report the data on central
hemodynamics. We saw in multiple sets of guidelines cited in the beginning of
this review that the only indication for inotropes in HF is low output syndrome.
Meanwhile, very few papers provide hemodynamic data. It means, that in most
studies, cardiac index/cardiac output were not even measured, and patients were
enrolled based on symptomatic HF and decreased left ventricular ejection
fraction, which is not an equivalent for low output syndrome. Moreover, in the
OPTIME-CHF trial, patients were excluded if their doctors thought that inotropes
were indicated 55. Therefore, the effects of inotropes were tested on patients
The VAD Journal: http://dx.doi.org/10.13023/VAD.2015.09
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who did not have indications for them, which is the best way to evaluate for side
effects without therapeutic benefits.
In summary, most randomized controlled trials with inotropes share
following features:


They were performed with pharmacologic agents that are currently
not in use. The reason for them being no longer used is the fact
that they increase mortality. This does not mean, however, that
the effects of the drugs, which proved to be detrimental, can be
extrapolated to currently used agents.



They were performed in the years when automatic cardiovertersdefibrillators were not recommended for primary prevention, and
an excess of sudden death may not be pertinent to current
situation when the patients with advanced cardiomyopathy are
protected with implanted defibrillators.



They were performed on patients who did not have any evidence
of low output syndrome and therefore did not have indications for
inotropes.

Conclusions
Randomized controlled trials with inotropes share certain common features: they
were performed with inotropes that are not currently in use; they were performed
before the time when automated cardioverter-defibrilators became standard of
care for primary prevention of sudden cardiac death; and they were performed on
patients without evidence of low output heart failure and without indications for
inotropes. Thus, these studies may not be generalizable to our current clinical
practice.
Currently, there is no evidence to suggest that in patients with low output
syndrome, treated according to the current guidelines, and protected by
implantable cardioverters-defibrillators, inotropes increase mortality. To the
contrary, recognition of the state of inotrope dependency is incompatible with the
statement that inotropes increase mortality.
.
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Table 3. Randomized control trials of inotropes in heart failure: poor outcomes of inotropes
Source, design

N

Follow-up

Cohn et al, 1998 53

3833

286 days

Inotrope

Vesnarinone,
oral

Vesnarinone Trial,
randomized to
vesnarinone in two
different doses and
placebo

Cardiac
index at
baseline

Mortality

Other Outcomes in the
Inotrope group versus
Placebo

Not
reported

Mortality:

Improved quality of life

Vesnarinone lower dose:
21%
Vesnarinone higher
dose: 22.9%
Placebo: 18.9%, p<0.02
(versus placebo), the
difference is presumably
due to sudden
(arrhythmic) death.

Cowley et al., 1994 52

151

One year

Enoximone,
oral

Not
reported

The Enoximone trial

Number of deaths:

Improved quality of life

Enoximone: 27
Placebo: 18, p<0.05

A randomized, double
blind, placebo controlled
trial: Enoximone vs
placebo

Sudden deaths:
Enoximone: 11
Placebo: 5
Progressive HF death:
Enoximone: 12
Placebo: 11
The trial was ended
early because of an
excess mortality in the
patients
treated with enoximone

Uretsky et al., 1990

51

102

4 months

Enoximone,
oral

Not
reported

Mortality:

Enoximone trial

Enoximone: 5 patients

Double-blind,
randomized, placebocontrolled

Placebo: 0 patients,
p<0.05

Enoximone vs placebo

No differences in
symptoms or exercise
duration at the end of 4
months.

Two deaths were
sudden, two were from
progressive HF, and one
was from acute
myocardial infarction.
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Hampton et al., 199754

1906

About one
year

Ibopamine,
oral

Not
reported

Randomized, placebocontrolled

Mortality:
Ibopamine: 232 (25%)
Placebo:193 (20%)

Ibopamine vs placebo
Relative risk 1.26 [95%
CI 1.04-1.53], p = 0.017.
The trial was stopped
early, because of an
excess of deaths in the
ibopamine group
Packer et al., 1991

1 088

6 months

Oral
milrinone

Not
reported

Mortality from all
causes:

55

Hospitalizations:
Milrinone 44%

Milrinone: 30%
Placebo 39%, p = 0.041

Prospective
Randomized Milrinone
Survival Evaluation
(PROMISE) trial

Placebo: 24%
A 28 % increase in all
cause mortality, p =
0.038, and a 34%
increase in
cardiovascular mortality,
p = 0.016). The trial
stopped prematurely
because of survival
compromise on
milrinone.

Double blind,
randomized
Oral milrinone vs
placebo

The Xamoterol in
Severe Heart Failure
Study, 1990 74.
Randomized, doubleblind, placebo-controlled

516

13 weeks

Xamoterol,
oral (beta
receptor
agonist)

Not
reported

Mortality:
Xamoterol 9.1%
Placebo: 3.7%, p=0.02

Randomization:
xamoterol vs placebo
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Table 4. Randomized control trials of inotropes in heart failure: neutral outcomes of inotropes
Source, design

N

Follow-up

Inotrope

Cardiac
index at
baseline

Mortality

Other Outcomes in the
Inotrope group versus
Placebo

Cuffe et al., 2002 58

951

60 days

IV milrinone

Not
reported

In-hospital mortality

Outcomes of a
Prospective Trial of
Intravenous Milrinone for
Exacerbations
(OPTIME-HF) trial:
randomized, doubleblind, placebocontrolled.

Milrinone: 3.8%

Composite incidence of
death or readmission: no
difference

Placebo: 2.3%

Milrinone: 35%

60-day mortality

Placebo: 35.3%

Milrinone vs placebo

No difference

Milrinone: 10.3%
Placebo: 8.9%

The median number of
days hospitalized for
cardiovascular causes
within 60 days after
randomization:
No difference

Metra et al., 2009 60

1854

17 months

Enoximone,
oral

Not
reported

All-cause mortality: no
difference

The 6 minute walk distance
increased with enoximone,
compared with placebo, in
ESSENTIAL-I (p = 0.025,
not reaching, however, the
pre-specified criterion for
statistical significance of p<
0.020

140

3-6
months

Milrinone,
oral

Not
reported

No mortality difference.

Improved exercise capacity
on milrinone

The Studies of Oral
Enoximone Therapy in
Advanced HF
(ESSENTIAL), two
identical, randomized,
double-blind, placebocontrolled trials differed
only by location
Colucci et al., 1993 62
Two randomized
placebo controlled trials:
milrinone vs placebo

Dibianco et al., 1984 75
Randomized doubleblind withdrawal study

Trials terminated
prematurely because of
the release of the
unfavorable results of
the other trial
52

3 months

Not
reported

No difference in cardiac
performance or in
rehospitalizations or
functional status

Patients who responded
to amrinone in the first
phase of the trial, were
randomized to continue
amrinone or to change
to placebo
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Elis et al., 1998 63

19

6 months

Randomized, double
blind, placebo controlled

Dobutamine
IV,
intermittent

Not
reported

The median survival
Dobutamine: 4.6 months

No difference between the
number of admissions for
HF

Placebo 8 months
Dobutamine vs placebo
over a 24-hour period
every 2 to 3 weeks.
Erlemeier et al., 1992

64

No difference

20

4 weeks

Dobutamine vs placebo

Dobutamine,
IV
intermittent

Not
reported

No mortality difference

Dobutamine: exercise
duration increase, body
weight decreased
Placebo: no change

Oliva et al., 1999 66

38

6 months

DICE
(Dobutaminanell'Insuffici
enza Cardiaca) trial:
Dobutamine vs standard
treatment

IV
dobutamine,
intermittent

1.89 +/0.1
L/min/m(
2)

Dobutamine: 5 deaths, 2
heart transplants

Hospitalizations for all
causes: no difference

Standard treatment: 3
deaths.

Dobutamine: 11 (7 for HF)

No difference

Standard treatment: 17 (11
for HF)
No difference in NYHA
class and in 6-minute
walking test.

Massie et al., 1985 65

99

12 weeks

Amrinone,
oral

Not
reported

No mortality difference

Exercise tolerance: no
difference

164

12 weeks

Enoximone,
oral

Not
reported

No mortality difference

Enoximone: greater
increases in exercise time
than placebo treatment at
weeks 4 and 8 but not
after 12 weeks.

161

6 months

Ibopamine,
oral

Not
reported

No mortality difference

Double-blind, placebocontrolled
Amrinone vs placebo
Narahara, 1991 67
The Western Enoximone
Study
Randomized, placebo
controlled
Enoximone vs placebo
Van Veldhuisen et al.,
1993 68
The Dutch Ibopamine
Multicenter Trial
Double-blind placebocontrolled, randomized
Ibopamine vs digoxin vs
placebo
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Table 5. Randomized control trials of inotropes in heart failure: good outcomes of inotropes
Source, design

Dubourg et al., 1990

69

N

Follow-up

Inotrope

Cardiac
index at
baseline

Mortality

Other Outcomes in the
Inotrope group versus
Placebo

30

31 days

Enoximone,
oral

2.17 +/0.7
L/min/m2

Mortality

Symptoms improvement on
enoximone

A double-blind,
randomized trial

Enoximone: 1
Placebo: 3

Enoximone vs. placebo
Feldman et al, 2007 61.
EMOTE trial
(Enoximone in
Intravenous InotropeDependent Subjects
Study

201

6 months

Oral
enoximone

Not
reported

Alive and free of IV
inotropes at 30 days
Enoximone: 62 (61.4%)
Placebo: 51 (51%)
At 60 days

Enoximone or placebo.

Enoximone: 46.5%

Enoximone was used to
wean patients from IV
inotropes

Placebo: 30%,
p = 0.016
Time to death or reinitiation of IV inotropes
At 6 months:
HR 0.76 [95% CI 0.551.04])
At 60 days:
HR 0.62 [95% CI 0.430.89], p = 0.009
At 90 days:
HR 0.69 [95% CI 0.490.97], p = 0.031,
favoring enoximone.

Feldman et al., 1993 70

477

6 months

Vesnarinone,
oral

Not
reported

Mortality plus worsening
HF:

Vesnarinone Study
Vesnarinone:26
Randomized, doubleblind, placebo-controlled
Vesnarinone vs
placebo

Placebo: 50, p= 0.003

Vesnarinone: quality of life
improved to a greater
extent than in the placebo
group over 12 weeks (P =
0.008)

A 62 % reduction (95%
CI, 28 - 80 %) in the risk
of dying from any cause
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among the patients
receiving vesnarinone
Nanas et al., 2004 57

30

6 months

Randomized, doubleblind, placebo-controlled
clinical trial.

Dobutamine,
IV

2.3 ± 0.7
L/min/m(
2)

Intermittent,
plus
amiodarone

Survival
Dobutamine plus
amiodarone vs placebo
plus amiodarone
HR=0.403; 95% CI=
0.164 -0.992; p = 0.048

Dobutamine vs placebo

1-year survival estimate
Dobutamine plus
amiodarone: 69%
Placebo plus
amiodarone:28%,
p<0.05
2-year survival estimate
Dobutamine plus
amiodarone: 44%
Placebo plus
amiodarone: 21%,
p<0.05
Likoff et al., 1984 71

9

Two 13
week
stages

Amrinone, IV

1.9+/0.2L/min/
m2

Placebo: 7 patients had a
significant deterioration of
symptoms or exercise
tolerance, or both. After 4
weeks of readministration
of amrinone, clinical status
improved

17

12 weeks

Enoximone,
IV and oral,
in a 2-part
study

3.42 +/0.72
L/min/m2
(after
Enoximo
ne IV)

Enoximone: left ventricular
ejection fraction improved
from 30.1 +/- 6.8% to 33.9
+/- 9.9%

Randomized, double
blind, placebo controlled
After being stabilized on
amrinone, patients were
randomized into
continuation on
amrinone or withdrawal
of amrinone
Khalife et al., 1987 76
Double-blind,
randomized, placebo
controlled
Randomization: after the
first phase when IV
enoximone was given to
all patients, they were
randomized into oral
Enoximone or placebo.

Placebo: unchanged
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